Global Digital Therapeutics Market - 2025-2033

Global Digital Therapeutics Market: Industry Outlook

The global digital therapeutics market reached US$ 6.84 Billion in 2024 and is expected to reach US$ 39.52 Billion by 2033, growing at a CAGR of 21.6% during the forecast period 2025-2033.

The global digital therapeutics market is experiencing promising growth due to the rising incidence of chronic conditions, increasing healthcare costs, and growing demand for personalized and preventive healthcare solutions. Digital therapeutics are applications that deliver therapeutic interventions, primarily based on evidence. These rely on software applications to treat or prevent illnesses or to offer management for almost every type of medical condition, posing a revolutionary complement- or even an alternative-to traditional therapies.

Moreover, continued support by governments, regulatory approvals (e.g., U.S. FDA and CE marking in Europe), coupled with growing clinical evidence backing the efficacy of digital therapeutics, are building up the momentum for adoption in various healthcare systems. More recently, with an unprecedentedly high rate, the COVID-19 scenario has emerged as an enabler in adopting and integrating digital health technologies, which puts a location-based view of healthcare, greater scalability, and remote patient-centric care in greater demand. Diabetes and obesity are some of the prominent therapeutic areas where DTx comes into play.

Global Digital Therapeutics Market Dynamics: Drivers & Restraints

Driver: Rising prevalence of chronic diseases

The global digital therapeutics market is experiencing growth due to the increasing prevalence of chronic diseases like diabetes, cardiovascular diseases, respiratory diseases, obesity, and mental health disorders.

For instance, chronic diseases, or non-communicable diseases, are a major global health concern, accounting for 73% of all deaths worldwide. The CDC reports that an estimated 129 million people in the US have at least one major chronic disease, and this prevalence is on the rise.

Traditional healthcare systems struggle to provide continuous, personalized, and cost-effective care for these long-term conditions. Digital therapeutics offer scalable solutions through software programs that help patients manage and improve their health outcomes outside of conventional clinical settings.

These solutions support behavior modification, medication adherence, remote monitoring, and real-time feedback, which are crucial for managing chronic diseases effectively.

Governments and healthcare providers are also adopting DTx to reduce hospital readmissions and healthcare costs. The demand for non-invasive, patient-centered, and easily accessible treatment options is driving the market, making digital therapeutics an integral part of modern chronic disease management strategies worldwide.

Driver: Increasing technological advancements

The global digital therapeutics market is experiencing rapid growth due to technological advancements in areas like artificial intelligence, machine learning, big data analytics, cloud computing, and IoT. These technologies enable personalized treatment plans, real-time patient monitoring, predictive analytics for disease progression, and adaptive interventions based on user behavior and health data. Wearable devices and mobile health apps integrated with AI algorithms provide continuous feedback and behavioral coaching, improving patient adherence and clinical outcomes.

Digital biomarkers and remote diagnostic tools enhance the precision of DTx platforms. The interoperability of digital health systems with electronic health records supports seamless data exchange between patients and healthcare providers, promoting better clinical decision-making. Technological capabilities are expanding the therapeutic scope of digital health products, improving scalability, cost-efficiency, and accessibility, solidifying the market's role as a cornerstone.

Restraint: Limiting the adoption of therapeutics

The market is hindered by several factors in the early phase of development, some of which are limiting the adoption, high cost of digital therapeutics, patient data privacy concerns, and unstable payment models could hurt the market.

This market represents an emerging field of software and device-driven products intended to prevent, manage, or treat medical conditions. However, increasing issues related to cybersecurity are a major concern limiting the adoption of therapeutics. For instance, in September 2023, the risk of cyberattacks on digital therapeutics apps increased compared to previous years. The cyberattacks are due to the increased availability of more users and the rise in patient health information.

Opportunity: Expansion into mental health and neurological disorders

The global digital therapeutics market is poised to expand into mental health and neurological disorders, as these areas face significant treatment gaps, stigma, and limited access to traditional care. Digital therapeutics offer scalable, discreet, and easily accessible solutions for cognitive behavioral therapy, mindfulness training, mood tracking, and neurological assessments via mobile apps or web-based platforms.

These tools enable continuous monitoring and personalized interventions without in-person visits, addressing accessibility and affordability issues, especially in underserved or rural regions. With growing societal acceptance of mental health care and a push for early diagnosis and intervention, DTx products targeting these conditions are gaining clinical validation and regulatory support.

Collaboration between neuroscientists, clinicians, and digital health developers is fostering innovation, making the expansion into mental and neurological health a transformative growth avenue.

Global Digital Therapeutics Market Segment Analysis

The global digital therapeutics market is segmented based on device type, application, sales channel, and region.

Product Type

The software segment from the product type is expected to hold 58.14% of the digital therapeutics market

The software segment holds a major portion of the digital therapeutics market share and is expected to continue to hold a significant portion of the digital therapeutics market share during the forecast period.

The digital therapeutics market is segmented based on the product type as software, devices, and others. The software segment accounts for the highest market share due to the increasing demand for software to reduce healthcare costs worldwide. The software also provides regular online assistance from certified doctors. The market is dominated by several digital therapeutics software that help patients maintain their proper diet, track health data, and perform daily physical activities.

For instance, in April 2025, Click Therapeutics, a leader in prescription medical treatments, launched an updated brand identity and website to reflect its evolution and vision for the future of medicine. The update follows a year of significant successes, including FDA clearance of the first prescription digital therapeutic for major depressive disorder symptoms, the CT-132 pivotal study for episodic migraine prevention, the launch of Click SE, and completed Series C financing with Dassault Systèmes and Medidata.

Global Digital Therapeutics Market - Geographical Analysis

North America dominated the global digital therapeutics market with the highest share of 42.3% in 2024

North America holds a substantial position in the digital therapeutics market and is expected to hold most of the market share due to the patient-centric healthcare approach for patient wellness, growing improvement in the reimbursement structure for digital therapeutics, and other factors.

Moreover, an increasing number of collaborations and agreements amongst the key players to focus on the research and development of these products is expected to increase the introduction of these devices in the region.

For instance, in October 2024, the Center for Technology and Behavioral Health (CTBH) at the Geisel School of Medicine at Dartmouth is partnering with Boehringer Ingelheim to develop digital therapeutics for serious mental illness. The collaboration will use academic research and healthcare industry strengths to create tools to tackle the global mental health crisis. CTBH's founding director, Lisa Marsch, emphasizes the importance of bringing the best science to create effective tools and ensuring they have a real impact on people's lives globally.

Moreover, in October 2024, Click Therapeutics, Inc., a leader in digital therapeutics as prescription medical treatments, announced the launch of Software-Enhanced Drug therapies, part of a new product offering called Click SE. With this launch, Click Therapeutics is creating a novel category of prescription digital therapeutic products in view of the increasing engagement in the U.S. Food and Drug Administration (FDA) draft guidance on the Prescription Drug-Use Related Software (PDURS). Hence, the above-mentioned factors help the North America region to grow during the forecast period. Together, these factors contribute to sustained market growth and dominance in the region.

Asia-Pacific is the global digital therapeutics market with a market share of 21.5% in 2024

The Asia-Pacific region is considered the largest emerging growth opportunity in the global digital therapeutics market, encompassed by a range of demographic, technological, and healthcare system-related factors. Asia has seen a rapid rise in chronic illnesses such as diabetes, hypertension, and mental health disorders.

Countries such as China, India, Japan, and South Korea have made significant investments in developing digital health infrastructure and in promulgating regulations that create an accommodating environment for DTx adoption. Furthermore, a very large tech-savvy population is willing to adopt digital tools for disease management and wellness, speeding market growth.

For instance, in February 2025, Hyfe, an AI-powered respiratory care company, partnered with Kyorin Pharmaceutical to develop and commercialize its prescription digital therapeutic (DTx) for treating chronic cough in Japan. DTx uses behavioral cough suppression therapy (BCST) and cough monitoring technology, which can improve cough outcomes in up to 87% of patients.

Global Digital Therapeutics Market - Key Players

The major global players in the digital therapeutics market include Teladoc Health, 2Morrow Inc, Omada Health Inc, Voluntis Inc, ResMed Inc (Propeller Health), Kaia Health, Biofourmis, Click Therapeutics, Inc, Welldoc's BlueStar, Lark Technologies, Inc., and among others

Global Digital Therapeutics Market – Key Developments

• In April 2025, Click Therapeutics obtained FDA marketing authorization for CT-132, the first prescription digital therapeutic for episodic migraine prevention. The De Novo Classification Request was granted for patients aged 18 and older, intended for adjunctive use alongside acute and other migraine treatments. The authorization is based on data from the ReMMi-D study and clinical results from the ReMMiD-C bridging study.